vs

Side-by-side financial comparison of COMTECH TELECOMMUNICATIONS CORP (CMTL) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.

CATALYST PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($152.6M vs $111.0M, roughly 1.4× COMTECH TELECOMMUNICATIONS CORP). CATALYST PHARMACEUTICALS, INC. runs the higher net margin — 34.5% vs -14.3%, a 48.8% gap on every dollar of revenue. On growth, CATALYST PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (7.6% vs -4.1%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $4.8M). Over the past eight quarters, CATALYST PHARMACEUTICALS, INC.'s revenue compounded faster (24.5% CAGR vs -9.0%).

Comtech Telecommunications Corp is a global provider of advanced communication technologies, including satellite communication systems, terrestrial network infrastructure, and location-based services. It serves government, defense, mobile network operator, and enterprise clients across North America, Europe, and Asia Pacific, focusing on reliable, secure connectivity solutions for critical use cases.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CMTL vs CPRX — Head-to-Head

Bigger by revenue
CPRX
CPRX
1.4× larger
CPRX
$152.6M
$111.0M
CMTL
Growing faster (revenue YoY)
CPRX
CPRX
+11.7% gap
CPRX
7.6%
-4.1%
CMTL
Higher net margin
CPRX
CPRX
48.8% more per $
CPRX
34.5%
-14.3%
CMTL
More free cash flow
CPRX
CPRX
$40.0M more FCF
CPRX
$44.9M
$4.8M
CMTL
Faster 2-yr revenue CAGR
CPRX
CPRX
Annualised
CPRX
24.5%
-9.0%
CMTL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CMTL
CMTL
CPRX
CPRX
Revenue
$111.0M
$152.6M
Net Profit
$-15.9M
$52.7M
Gross Margin
33.1%
82.9%
Operating Margin
-2.5%
40.5%
Net Margin
-14.3%
34.5%
Revenue YoY
-4.1%
7.6%
Net Profit YoY
89.3%
-5.8%
EPS (diluted)
$-0.67
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMTL
CMTL
CPRX
CPRX
Q4 25
$111.0M
$152.6M
Q3 25
$130.4M
$148.4M
Q2 25
$126.8M
$146.6M
Q1 25
$126.6M
$141.4M
Q4 24
$115.8M
$141.8M
Q3 24
$126.2M
$128.7M
Q2 24
$128.1M
$122.7M
Q1 24
$134.2M
$98.5M
Net Profit
CMTL
CMTL
CPRX
CPRX
Q4 25
$-15.9M
$52.7M
Q3 25
$7.9M
$52.8M
Q2 25
$33.9M
$52.1M
Q1 25
$-48.7M
$56.7M
Q4 24
$-148.4M
$55.9M
Q3 24
$-90.8M
$43.9M
Q2 24
$2.8M
$40.8M
Q1 24
$-10.6M
$23.3M
Gross Margin
CMTL
CMTL
CPRX
CPRX
Q4 25
33.1%
82.9%
Q3 25
31.2%
84.7%
Q2 25
30.7%
85.9%
Q1 25
26.7%
87.3%
Q4 24
12.5%
84.7%
Q3 24
21.5%
85.0%
Q2 24
30.4%
87.4%
Q1 24
32.2%
87.3%
Operating Margin
CMTL
CMTL
CPRX
CPRX
Q4 25
-2.5%
40.5%
Q3 25
1.4%
44.7%
Q2 25
-1.2%
45.2%
Q1 25
-8.1%
44.8%
Q4 24
-111.5%
44.3%
Q3 24
-64.6%
39.6%
Q2 24
-2.7%
44.2%
Q1 24
2.2%
27.5%
Net Margin
CMTL
CMTL
CPRX
CPRX
Q4 25
-14.3%
34.5%
Q3 25
6.1%
35.6%
Q2 25
26.8%
35.6%
Q1 25
-38.5%
40.1%
Q4 24
-128.2%
39.4%
Q3 24
-71.9%
34.1%
Q2 24
2.2%
33.2%
Q1 24
-7.9%
23.6%
EPS (diluted)
CMTL
CMTL
CPRX
CPRX
Q4 25
$-0.67
$0.40
Q3 25
$-0.41
$0.42
Q2 25
$-0.49
$0.41
Q1 25
$-0.76
$0.45
Q4 24
$-5.29
$0.44
Q3 24
$-3.48
$0.35
Q2 24
$-0.04
$0.33
Q1 24
$-1.07
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMTL
CMTL
CPRX
CPRX
Cash + ST InvestmentsLiquidity on hand
$43.6M
$709.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$85.6M
$954.3M
Total Assets
$734.1M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMTL
CMTL
CPRX
CPRX
Q4 25
$43.6M
$709.2M
Q3 25
$40.0M
$689.9M
Q2 25
$28.4M
$652.8M
Q1 25
$26.7M
$580.7M
Q4 24
$29.6M
$517.6M
Q3 24
$32.4M
$442.3M
Q2 24
$27.2M
$375.7M
Q1 24
$40.0M
$310.4M
Stockholders' Equity
CMTL
CMTL
CPRX
CPRX
Q4 25
$85.6M
$954.3M
Q3 25
$104.4M
$920.2M
Q2 25
$115.4M
$856.0M
Q1 25
$128.7M
$794.3M
Q4 24
$150.4M
$727.6M
Q3 24
$306.3M
$660.9M
Q2 24
$406.4M
$608.7M
Q1 24
$407.0M
$561.4M
Total Assets
CMTL
CMTL
CPRX
CPRX
Q4 25
$734.1M
$1.1B
Q3 25
$740.8M
$1.1B
Q2 25
$751.1M
$971.9M
Q1 25
$770.6M
$908.9M
Q4 24
$793.2M
$851.4M
Q3 24
$793.2M
$772.0M
Q2 24
$991.0M
$706.4M
Q1 24
$996.8M
$646.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMTL
CMTL
CPRX
CPRX
Operating Cash FlowLast quarter
$8.1M
$44.9M
Free Cash FlowOCF − Capex
$4.8M
$44.9M
FCF MarginFCF / Revenue
4.3%
29.4%
Capex IntensityCapex / Revenue
2.9%
0.0%
Cash ConversionOCF / Net Profit
0.85×
TTM Free Cash FlowTrailing 4 quarters
$12.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMTL
CMTL
CPRX
CPRX
Q4 25
$8.1M
$44.9M
Q3 25
$11.4M
$32.4M
Q2 25
$2.3M
$71.3M
Q1 25
$-234.0K
$60.0M
Q4 24
$-21.8M
$70.9M
Q3 24
$-9.5M
$72.9M
Q2 24
$-3.8M
$64.1M
Q1 24
$-26.7M
$31.9M
Free Cash Flow
CMTL
CMTL
CPRX
CPRX
Q4 25
$4.8M
$44.9M
Q3 25
$9.4M
Q2 25
$-160.0K
$71.3M
Q1 25
$-1.9M
Q4 24
$-24.2M
$70.8M
Q3 24
$-12.4M
$72.6M
Q2 24
$-6.5M
$64.1M
Q1 24
$-30.9M
$31.7M
FCF Margin
CMTL
CMTL
CPRX
CPRX
Q4 25
4.3%
29.4%
Q3 25
7.2%
Q2 25
-0.1%
48.6%
Q1 25
-1.5%
Q4 24
-20.9%
49.9%
Q3 24
-9.8%
56.4%
Q2 24
-5.0%
52.3%
Q1 24
-23.0%
32.2%
Capex Intensity
CMTL
CMTL
CPRX
CPRX
Q4 25
2.9%
0.0%
Q3 25
1.6%
0.0%
Q2 25
1.9%
0.0%
Q1 25
1.3%
0.0%
Q4 24
2.1%
0.1%
Q3 24
2.3%
0.2%
Q2 24
2.1%
0.0%
Q1 24
3.2%
0.2%
Cash Conversion
CMTL
CMTL
CPRX
CPRX
Q4 25
0.85×
Q3 25
1.45×
0.61×
Q2 25
0.07×
1.37×
Q1 25
1.06×
Q4 24
1.27×
Q3 24
1.66×
Q2 24
-1.36×
1.57×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMTL
CMTL

Satellite And Space Communications Segment$55.1M50%
Transferred At Point In Time$39.4M36%
Satellite And Space Communications$16.3M15%
Terrestrial And Wireless Networks$1.1M1%

CPRX
CPRX

Firdapse$97.6M64%
Agamree$35.3M23%
Fycompa$19.6M13%

Related Comparisons